(COV) Covivio - Overview
Exchange: PA •
Country: France •
Currency: EUR •
Type: Common Stock •
ISIN: FR0000064578
Stock: Hotels, Offices, Residences, Spaces
Total Rating 49
Risk 70
Buy Signal -0.29
| Risk 5d forecast | |
|---|---|
| Volatility | 32.5% |
| Relative Tail Risk | -2.75% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.64 |
| Alpha | 12.15 |
| Character TTM | |
|---|---|
| Beta | 0.188 |
| Beta Downside | -0.164 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.62% |
| CAGR/Max DD | 0.25 |
Description: COV Covivio March 05, 2026
Covivio (COV) is a European real estate company. It operates across various segments, including offices, hotels, and residential properties. This diversified approach is common among large real estate investment trusts (REITs) seeking stable income streams.
The company focuses on creating adaptable urban spaces, aligning with the evolving demands for integrated work, travel, and living environments. Real estate companies often aim to develop properties that cater to mixed-use trends, enhancing their appeal and value.
Covivio emphasizes sustainable relationships and responsible real estate operations, addressing stakeholders from customers to future generations. For further in-depth analysis, consider exploring ValueRay.
Headlines to watch out for
- European real estate demand impacts rental income
- Interest rate fluctuations affect financing costs
- Regulatory changes influence property development
- Economic downturns reduce hotel and office occupancy
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 806.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 2.33 > 1.0 |
| NWC/Revenue: -107.0% < 20% (prev 6.74%; Δ -113.8% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.81b > Net Income 806.9m |
| Net Debt (9.43b) to EBITDA (1.66b): 5.67 < 3 |
| Current Ratio: 0.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (110.8m) vs 12m ago 10.65% < -2% |
| Gross Margin: 63.87% > 18% (prev 0.73%; Δ 6313 % > 0.5%) |
| Asset Turnover: 9.82% > 50% (prev 11.19%; Δ -1.37% > 0%) |
| Interest Coverage Ratio: 38.66 > 6 (EBITDA TTM 1.66b / Interest Expense TTM 27.4m) |
Altman Z'' 0.47
| A: -0.09 (Total Current Assets 1.21b - Total Current Liabilities 3.54b) / Total Assets 25.34b |
| B: 0.01 (Retained Earnings 341.4m / Total Assets 25.34b) |
| C: 0.05 (EBIT TTM 1.06b / Avg Total Assets 22.23b) |
| D: 0.68 (Book Value of Equity 8.61b / Total Liabilities 12.69b) |
| Altman-Z'' Score: 0.47 = B |
Beneish M
| DSRI: none (Receivables none/481.4m, Revenue 2.18b/2.14b) |
| GMI: 1.15 (GM 63.87% / 73.36%) |
| AQI: 1.01 (AQ_t 0.87 / AQ_t-1 0.87) |
| SGI: 1.02 (Revenue 2.18b / 2.14b) |
| TATA: -0.04 (NI 806.9m - CFO 1.81b) / TA 25.34b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of COV shares?
As of March 11, 2026, the stock is trading at EUR 57.75 with a total of 166,773 shares traded.
Over the past week, the price has changed by +0.09%, over one month by +5.19%, over three months by +7.34% and over the past year by +15.61%.
Over the past week, the price has changed by +0.09%, over one month by +5.19%, over three months by +7.34% and over the past year by +15.61%.
Is COV a buy, sell or hold?
Covivio has no consensus analysts rating.
What are the forecasts/targets for the COV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 63.1 | 9.3% |
| Analysts Target Price | - | - |
COV Fundamental Data Overview March 10, 2026
Market Cap USD = 7.35b (6.39b EUR * 1.1513 EUR.USD)
P/E Trailing = 15.305
P/E Forward = 11.5875
P/S = 5.8963
P/B = 0.7769
Revenue TTM = 2.18b EUR
EBIT TTM = 1.06b EUR
EBITDA TTM = 1.66b EUR
Long Term Debt = 8.60b EUR (from longTermDebt, two quarters ago)
Short Term Debt = 2.42b EUR (from shortTermDebt, two quarters ago)
Debt = 10.63b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.43b EUR (from netDebt column, last quarter)
Enterprise Value = 15.81b EUR (6.39b + Debt 10.63b - CCE 1.21b)
Interest Coverage Ratio = 38.66 (Ebit TTM 1.06b / Interest Expense TTM 27.4m)
EV/FCF = 20.76x (Enterprise Value 15.81b / FCF TTM 761.7m)
FCF Yield = 4.82% (FCF TTM 761.7m / Enterprise Value 15.81b)
FCF Margin = 34.90% (FCF TTM 761.7m / Revenue TTM 2.18b)
Net Margin = 36.97% (Net Income TTM 806.9m / Revenue TTM 2.18b)
Gross Margin = 63.87% ((Revenue TTM 2.18b - Cost of Revenue TTM 788.6m) / Revenue TTM)
Gross Margin QoQ = 70.12% (prev 62.50%)
Tobins Q-Ratio = 0.62 (Enterprise Value 15.81b / Total Assets 25.34b)
Interest Expense / Debt = 0.26% (Interest Expense 27.4m / Debt 10.63b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 794.4m (EBIT 1.06b * (1 - 25.00%))
Current Ratio = 0.34 (Total Current Assets 1.21b / Total Current Liabilities 3.54b)
Debt / Equity = 1.23 (Debt 10.63b / totalStockholderEquity, last quarter 8.61b)
Debt / EBITDA = 5.67 (Net Debt 9.43b / EBITDA 1.66b)
Debt / FCF = 12.37 (Net Debt 9.43b / FCF TTM 761.7m)
Total Stockholder Equity = 8.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.63% (Net Income 806.9m / Total Assets 25.34b)
RoE = 9.72% (Net Income TTM 806.9m / Total Stockholder Equity 8.30b)
RoCE = 6.27% (EBIT 1.06b / Capital Employed (Equity 8.30b + L.T.Debt 8.60b))
RoIC = 4.18% (NOPAT 794.4m / Invested Capital 19.02b)
WACC = 2.60% (E(6.39b)/V(17.02b) * Re(6.61%) + D(10.63b)/V(17.02b) * Rd(0.26%) * (1-Tc(0.25)))
Discount Rate = 6.61% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 5.19%
[DCF] Terminal Value 84.53% ; FCFF base≈508.4m ; Y1≈431.8m ; Y5≈329.9m
[DCF] Fair Price = 5.64 (EV 10.05b - Net Debt 9.43b = Equity 624.4m / Shares 110.7m; r=5.90% [WACC]; 5y FCF grow -18.26% → 2.90% )
EPS Correlation: -8.18 | EPS CAGR: -27.95% | SUE: 0.0 | # QB: 0
Revenue Correlation: 41.42 | Revenue CAGR: 16.03% | SUE: 0.22 | # QB: 0
EPS current Year (2026-12-31): EPS=4.89 | Chg7d=+0.076 | Chg30d=+0.167 | Revisions Net=+5 | Growth EPS=+7.0% | Growth Revenue=+7.2%
EPS next Year (2027-12-31): EPS=5.03 | Chg7d=+0.085 | Chg30d=+0.115 | Revisions Net=+5 | Growth EPS=+2.8% | Growth Revenue=+10.7%
[Analyst] Revisions Ratio: +1.00 (5 Up / 0 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 1.4% (Discount Rate 7.9% - Earnings Yield 6.5%)
[Growth] Growth Spread = +9.3% (Analyst 10.7% - Implied 1.4%)
P/E Trailing = 15.305
P/E Forward = 11.5875
P/S = 5.8963
P/B = 0.7769
Revenue TTM = 2.18b EUR
EBIT TTM = 1.06b EUR
EBITDA TTM = 1.66b EUR
Long Term Debt = 8.60b EUR (from longTermDebt, two quarters ago)
Short Term Debt = 2.42b EUR (from shortTermDebt, two quarters ago)
Debt = 10.63b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.43b EUR (from netDebt column, last quarter)
Enterprise Value = 15.81b EUR (6.39b + Debt 10.63b - CCE 1.21b)
Interest Coverage Ratio = 38.66 (Ebit TTM 1.06b / Interest Expense TTM 27.4m)
EV/FCF = 20.76x (Enterprise Value 15.81b / FCF TTM 761.7m)
FCF Yield = 4.82% (FCF TTM 761.7m / Enterprise Value 15.81b)
FCF Margin = 34.90% (FCF TTM 761.7m / Revenue TTM 2.18b)
Net Margin = 36.97% (Net Income TTM 806.9m / Revenue TTM 2.18b)
Gross Margin = 63.87% ((Revenue TTM 2.18b - Cost of Revenue TTM 788.6m) / Revenue TTM)
Gross Margin QoQ = 70.12% (prev 62.50%)
Tobins Q-Ratio = 0.62 (Enterprise Value 15.81b / Total Assets 25.34b)
Interest Expense / Debt = 0.26% (Interest Expense 27.4m / Debt 10.63b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 794.4m (EBIT 1.06b * (1 - 25.00%))
Current Ratio = 0.34 (Total Current Assets 1.21b / Total Current Liabilities 3.54b)
Debt / Equity = 1.23 (Debt 10.63b / totalStockholderEquity, last quarter 8.61b)
Debt / EBITDA = 5.67 (Net Debt 9.43b / EBITDA 1.66b)
Debt / FCF = 12.37 (Net Debt 9.43b / FCF TTM 761.7m)
Total Stockholder Equity = 8.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.63% (Net Income 806.9m / Total Assets 25.34b)
RoE = 9.72% (Net Income TTM 806.9m / Total Stockholder Equity 8.30b)
RoCE = 6.27% (EBIT 1.06b / Capital Employed (Equity 8.30b + L.T.Debt 8.60b))
RoIC = 4.18% (NOPAT 794.4m / Invested Capital 19.02b)
WACC = 2.60% (E(6.39b)/V(17.02b) * Re(6.61%) + D(10.63b)/V(17.02b) * Rd(0.26%) * (1-Tc(0.25)))
Discount Rate = 6.61% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 5.19%
[DCF] Terminal Value 84.53% ; FCFF base≈508.4m ; Y1≈431.8m ; Y5≈329.9m
[DCF] Fair Price = 5.64 (EV 10.05b - Net Debt 9.43b = Equity 624.4m / Shares 110.7m; r=5.90% [WACC]; 5y FCF grow -18.26% → 2.90% )
EPS Correlation: -8.18 | EPS CAGR: -27.95% | SUE: 0.0 | # QB: 0
Revenue Correlation: 41.42 | Revenue CAGR: 16.03% | SUE: 0.22 | # QB: 0
EPS current Year (2026-12-31): EPS=4.89 | Chg7d=+0.076 | Chg30d=+0.167 | Revisions Net=+5 | Growth EPS=+7.0% | Growth Revenue=+7.2%
EPS next Year (2027-12-31): EPS=5.03 | Chg7d=+0.085 | Chg30d=+0.115 | Revisions Net=+5 | Growth EPS=+2.8% | Growth Revenue=+10.7%
[Analyst] Revisions Ratio: +1.00 (5 Up / 0 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 1.4% (Discount Rate 7.9% - Earnings Yield 6.5%)
[Growth] Growth Spread = +9.3% (Analyst 10.7% - Implied 1.4%)